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Abstract
Background: Human papillomavirus (HPV) is the main etiological agent of cervical cancer, the third most common
cancer among women globally and the second most frequent in Mexico. Persistent infection with high-risk HPV
genotypes is associated with premalignant lesions and cervical cancer development. HPVs considered as low risk or
not yet classified, are often found in coinfection with different HPV genotypes. Indeed, HPV62 is one of the most
prevalent HPV detected in some countries, but there is limited information about its prevalence in other regions
and there are no HPV62 variants currently described. The aim of this study was to determine the prevalence of
HPV62 in cervical samples from Mexican women and to identify mutations in the L1, E6 and E7 genes, which have
never been reported in our population.
Methods: HPV screening was performed by Cobas HPV Test in women who attended prevention health programs
and dysplasia clinics. All HPV positive samples (n = 491) and 87 additional cervical cancer samples were then
genotyped with Linear Array HPV Genotyping test. Some samples were selected to corroborate genotyping by
Next-Generation sequencing. On the other hand, nucleotide changes in L1, E6 and E7 genes were determined using
PCR, Sanger sequencing and analysis with the CLC-MainWorkbench 7.6.1 software. L1 protein structure was predicted
with the I-TASSER server.
Results: Using Linear Array, HPV62 prevalence was 7.6% in general population, 8% in Cervical Intraepithelial Neoplasia
grade 1 (CIN1) samples and 4.6% in cervical samples. The presence of HPV62 was confirmed with Next-Generation
sequencing. Regarding L1 gene, novel sequence variations were detected, but they did not alter the tertiary structure
of the protein. Moreover, several nucleotide substitutions were found in E6 and E7 genes compared to reference
HPV62 genomic sequence. Specifically, three non-synonymous sequence variations were detected, two in E6 and one
in E7.
Conclusions: HPV62 is a frequent HPV genotype found mainly in general population and in women with CIN1, and in
90.5% of the cases it was found in coinfection with other HPVs. Novel nucleotide changes in its L1, E6 and E7 genes
were detected, some of them lead to changes in the protein sequence.
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Background
Cervical Cancer (CC) is the fourth leading cause of
cancer deaths in women worldwide with an estimate of
more than 528,000 new diagnosed cases and 266,000
deaths in 2012. More than 85% of deaths occur in devel-
oping countries and in particular, in Mexico, CC is the
second most frequent cancer leading to 4,769 deaths in
2012 [1]. This pathology is directly associated with HPV
(Human Papillomavirus) infection and to date, around
200 HPVs have been described [2, 3]. Mucosal HPVs are
grouped into low risk (LR-HPVs) and high risk HPVs
(HR-HPVs), the latter being considered the etiologic
agents of CC [3]. The Alphapapillomavirus genus
harbors more than 60 types of HPVs, including the
oncogenic HPVs associated to anogenital cancers
according to the International Agency for Research on
Cancer (IARC): types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66 and 68 [4, 5]. Specifically, HPV16 and
HPV18 are found in around 70% of the CC cases world-
wide [6, 7].
HPVs have a circular double-stranded 8 kb DNA gen-
ome that typically contains eight genes [8]. The L1 gene,
which encodes the principal virus capsid protein, is used
for the classification and construction of phylogenetic
trees as it is well conserved among different HPVs. In
2004, the HPV classification criteria were defined based
on differences in the complete L1 Open Reading Frame
(ORF): different genera share less than 60% nucleotide
sequence identity, HPV species within a genus share
between 60 and 70% identity, HPV types share between
71 and 89% nucleotide identity, HPV subtypes differ in
2-10% and HPV variants differ in 1-2% within the L1
ORF [9]. In 2013, the term variant was proposed to also
include HPV subtypes. The use of full genome sequence
information, instead of the L1 ORF, was recommended
to classify a new variant genome. The alignment of
complete viral genomes began to define variant lineages
and sublineages using differences of 1-10% and 0.5-1%,
respectively [10].
HR-HPV genomes encode three oncoproteins ─E5,
E6 and E7─ that contribute to enhanced cell prolifera-
tion, initiation and progression of CC [11]. An interest-
ing review contrasts the activities of the human alpha-
PV oncoproteins with their non-oncogenic counterparts
based on cell culture studies [12]. The comparison of
activities of LR- and HR-HPVs would lead to the identifi-
cation of common activities probably needed for the viral
life cycle, while additional functions of HR-HPVs could be
crucial for the transformation/immortalization process.
HPV62 was characterized in 2004 by Fu et al. (acces-
sion number AY395706) from a cervical sample obtained
from a 45-year-old woman with normal cytology [13]
and it is considered as a LR-HPV. The E6 (447 bp), E7
(291 bp) and L1 (1512 bp) genes from this HPV62
reference genome (8092 bp) encode for 148, 96 and 503
amino acid proteins, respectively. In a first report includ-
ing cervical samples from mexican population, HPV62
was mainly detected in coinfection with other HPV
genotypes and it was found in 5.1% of HPV positive
patients with Cervical Intraepithelial Neoplasia Grade 1
(CIN1) and in 0.8% of HPV positive patients with CC
using Linear Array HPV Genotyping test [14]. The aim
of this study, was to determine the prevalence of this
genotype in a greater number of samples among Mexican
women and to detect possible mutations in L1, E6 and E7
genes of the HPV62 circulating in the Mexican popula-
tion. Until now, only two complete genome sequences
have been reported worldwide from 2 patients: the first
one in 2004 (AY395706) [13] and the second one very re-
cently uploaded (KU298924.1) [15].
Methods
Sample collection
All samples were collected by gynecologists with a cyto-
brush inserted into the endocervical canal and placed
into the transport medium PreservCyt (Hologic, Bed-
ford, MA). Three large groups of samples were included:
1) cervical samples from women (general population),
who attended cervical cancer prevention programs; 2)
cervical samples with CIN1 from women who attended
a Dysplasia Clinic, and 3) cervical samples with CC from
women who attended the Oncology Hospital. The first
group of samples include women from six different
States of the Mexican Republic (Aguascalientes, Colima,
Guanajuato, Jalisco, Michoacán, Nayarit and Yucatán),
and they were obtained from the Regional Hospital Dr.
Valentín Gómez Farías – ISSSTE (Guadalajara, Jalisco).
The samples from the second group were recruited at
the Dysplasia Clinic of the Regional General Hospital
No. 12 Lic. Benito Juárez – IMSS (Mérida, Yucatán), and
at the Dysplasia Clinic of the Western National Medical
Center – IMSS (Guadalajara, Jalisco). Finally, the last
group’s samples were obtained exclusively from the On-
cology Hospital of the Western National Medical Center
– IMSS (Guadalajara, Jalisco). In all cases, the samples
were taken as part of the routine diagnosis confirmation
and an aliquot of the PreservCyt solution was given for
our study, after informed consent was signed. Samples
with excess of blood and mucus in the PreservCyt solu-
tion, low DNA quantity or quality samples, were elimi-
nated. A total of 2835 samples were screened for HPV;
2399 from general population, 349 from Dysplasia
Clinics and 87 from Oncology Hospital. Concerning only
the first group of samples, the diagnosis was kept
anonymous for this study, as authorized in the ethically
approved protocol. However, the diagnosis of the second
(CIN1) and third (CC) group of samples was obtained
Artaza-Irigaray et al. Infectious Agents and Cancer  (2017) 12:15 Page 2 of 11
by colposcopic observation and confirmed by histo-
pathological analysis.
Samples were collected from July 2014 to July 2016.
As detailed in the section of ethical considerations,
collection of the samples from the different groups was
authorized by the ISSSTE and the National Committee
on Health Research and Ethics of the IMSS, for various
research protocols.
HPV screening and genotyping
The samples from the first and the second group were
first screened for HPV positivity with the Cobas HPV
Test (Roche Molecular Systems, Inc). Afterwards, all
HPV positive samples were genotyped with the Linear
Array HPV Genotyping test (LA), Roche Molecular
Diagnostics. Additionally, 48 CIN1 samples taken ran-
domly, were genotyped with the 454 Next-Generation
Sequencing (NGS) platform to confirm HPV genotyping.
Regarding the third group, all CC samples were geno-
typed with LA and 48 of them were also selected ran-
domly to confirm genotyping with NGS. The set of
PGMY11/09 primers (452 bp amplicon from nucleotide
949 to 1400 of L1 ORF) was used for NGS, as previously
described [16]. In addition, NGS was also performed
using the degenerated FAP primers set [17, 18]. A first
conventional Polymerase Chain Reaction (PCR) was
done with the primers FAP59 (forward 5′- TAACWG-
TIGGICAYCCWTATT - 3′) and FAP64 (reverse 5′-
CCWATATCWVHCATITCICCATC - 3′) to amplify a
478 bp fragment from the L1 region. PCR conditions
were: 94 °C for 3 min, 35 cycles at 94 °C for 45 s,
50 °C for 30 s and 72 °C for 1 min, finally 72 °C for
10 min. A second PCR was done with the 478 bp
amplicon using the following primers: Forward 5′-
[Universal Multiplicom tail A: AAGACTCGGCAG-
CATCTCCA] – [FAP6085: CCWGATCCHAATMRRT
TTGC]-3′. and Reverse 5′ [Universal Multiplicom tail
B: GCGATCGTCACTGTTCTCCA] – [FAP64 pri-
mer]. The resulting amplicon is of 377 bp (from
nucleotide 232 to 607 of L1 ORF). Universal Multipli-
com tails A and B were the same used in Cat. no.
MR-0020.024 (Multiplicom NV CFTR; Molecular
Diagnostics, Niel, Belgium). This second PCR was run
under the same conditions as the first PCR, except
for the annealing temperature that was changed to
47 °C. Amplicons were visualized by gel electrophor-
esis in a 1.5% agarose gel. HPV positive samples were
selected to undergo further screening by NGS using
Multiplex identifiers (MID) barcodes for each sample
as described in Flores-Miramontes et al. [16]. Quality
control of the obtained sequences was carried out
with the online platform Galaxy (version 16.04) and
they were analyzed with Roche′s GS Reference Map-
per Software (version 2.9), using as references all
human papillomavirus sequences from the Papilloma-
virus Episteme (PaVE) database [3, 19].
Sanger sequencing for L1, E6 and E7 genes
E6, E7 and L1 genes were amplified from cervical sam-
ples positive to HPV62 by Linear Array using PCR with
the following primer pairs specific for each gene of inter-
est (all of them were designed with Oligo v6 software).
E6: forward 5′- GGTCAGCACAGTAGCAATGACT-3′
and reverse 5′- CGGGACGCTCTTGTAGGAC- 3′; E7:
forward 5′-CAGGAGTGTGGACAGGACGGTA- 3′ and
reverse 5′- GCATCGGCCATGTCACTTATG -3′; L1:
forward 5′- ACGCCTTCCTTCCCTGCAACTA - 3′
and reverse 5′-CACTGACAAACGCGCACAACAC-3′.
The reactions were performed in a final volume of 25 uL
containing at least 200 ng of genomic DNA, 200 uM of
each dNTP, 1X reaction buffer with 1.8 mM of MgCl2,
12.5 pmol of each primer, and 1.25 units of Fast Start
High Fidelity enzyme (Roche Applied Science, Cat. No.
04 738 284 001). PCR conditions were: initial denatur-
ation at 95 °C for 2 min, 35 cycles of 95 °C for 30 s,
annealing at 58 °C (HPV62-E6 and -E7) or 62 °C
(HPV62-L1) for 30 s, elongation at 72 °C for 45 s, and a
final extension at 72 °C for 7 min. Afterwards, 5 uL of
the PCR products were visualized on 1% agarose gel to
corroborate the presence and size of the amplicon, and
the other 20 uL were utilized for isopropanol purifica-
tion. Purified amplicons were sequenced with BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Cat. No. 4337455) using the above mentioned for-
ward primers for E6, E7, and L1 and additional primers
designed for L1, which is too long to be sequenced with
a single primer (5′-ACACGGAACGCATGGTATGGGC,
5′-GCAGAACCTTATGGCGATTGTA-3′ and 5′-TTG
TGCAAAATACAGTTAACCC-3′). Reactions were per-
formed in a final volume of 20 uL with around 50 ng of
DNA, 10 pmol of forward primer, 2 uL of 5X
Sequencing Buffer, and 4 uL of Ready Reaction
Premix. Cycling conditions were set as follows: initial
denaturation at 96 °C for 1 min, and 25 cycles at 96 °
C for 10 s, annealing at 50 °C for 5 s, elongation at
60 °C for 4 min. Finally, products were purified with
Centri-Sep Spin Columns (ABI, Cat. No. 401762), and
sequenced with the ABI PRISM 310 Genetic Analyzer
(Applied Biosystems).
Sequence alignments and L1 protein structure prediction
analysis
To detect genetic mutations or variants in E6, E7 and
L1, the obtained gene sequences were aligned to the
HPV62 reference sequence (reported as AY395706 in
the NCBI database) using the CLC-MainWorkbench
7.6.1 program (Qiagen). To look for amino acid changes,
the DNA sequences were translated into protein with
Artaza-Irigaray et al. Infectious Agents and Cancer  (2017) 12:15 Page 3 of 11
the same software, and aligned to the reference protein.
The phylogenetic tree showing alpha-3 group HPVs and
all HPV62 sequences obtained in this work, was
performed with MEGA v.7.014 software using Maximum
Likelihood statistical method.
Finally, the L1 protein structures were predicted with
the I-TASSER server (Iterative Threading ASSEmbly
Refinement), which identifies structural templates from
the Protein Data Bank by multiple threading approach
and constructs full-length atomic models by iterative tem-
plate fragment assembly simulations [20–23]. Protein
structure alignment was performed with CLC MainWork-
bench 7.6.1 program.
Results
HPV62 prevalence genotyped by Linear Array HPV
Genotyping Test
Regarding the first group of cervical samples described
in “Methods section” (general population of women who
attended cervical cancer prevention health programs),
from the 2399 samples screened for HPV positivity by
Cobas HPV Test, 291 were HPV positive (12.1%) and
22/291 (7.6%) were HPV62 positive. Concerning the
second group (CIN1 samples), from the 349 screened
with Cobas, 200 (57.3%) were HPV positive and 16/200
(8%) were HPV62 positive. Finally, the third group of
samples (CC samples) showed 100% of HPV positivity
with LA, and from those, only 4 samples (4.6%) were
HPV62 positive. It is important to highlight that in only
4 samples from the total of 42 HPV62 positive
samples, this genotype was found as single infection
(exclusively in CIN1 samples), and in the other 38
(90.5%) in coinfection with 1 to 5 additional HPV
genotypes (detailed in Table 1).
Interestingly, as depicted in Fig. 1, HPV62 was more
frequently found in coinfection with 16, 39, 59, 51 and
83 HPV genotypes.
HPV genotyping by NGS
To confirm HPV genotyping, 48 CIN1 samples were
sequenced with NGS, 8 of them HPV62 positive with
Linear Array. In those 8 samples, HPV62 presence was
corroborated using NGS; however, 3 additional samples
were positive to HPV62 only with the last methodology.
Concerning the presence of HPV62 exclusively in
cervical cancer, 48 samples diagnosed with squamous
cervical carcinoma were selected for HPV genotyping by
NGS (choosing preferentially those that showed more
than two HPV genotypes detected by Linear Array). To
detect a broader HPV genotype spectrum in those sam-
ples, NGS was performed utilizing PGMY11/09 and FAP
primer sets. As depicted in Table 2, four of the samples
mapped with high identity to HPV62, and they were
found in coinfection with additional HPV genotypes,
including beta-1 papillomavirus (12, 21 and 118), which
were only detected with FAP primers.
Nucleotide variations in HPV62-L1
To study whether the HPV62 circulating in the Mexican
population exhibits nucleotide changes in L1, all
HPV62-L1 sequences obtained by NGS with PGMY or
FAP primers (independently of the diagnosis of the sam-
ples) were aligned to the HPV62 complete genome
(AY395706). The contigs were obtained from 11 samples
amplified with PGMY primers and 9 samples amplified
with FAP primers. Alignment of the eleven HPV62-L1
contigs revealed the presence of 9 mutations distributed
among all the samples in the region amplified with
Table 1 HPV genotypes detected in coinfection with HPV62 by
Linear Array in each of the 38 HPV62 positive samples





Sample Code HPV genotypes
detected by
Linear Array
GP-1 16, 42, 58, 81, 83 GP-12 39, 59, 61
GP-2 31, 52, 61, 72, 84 GP-13 42, 45, 84
GP-3 39, 51, 56, 58, 84 GP-14 16, 18
GP-4 11, 52, 59, 83 GP-15 16, 51
GP-5 31, 39, 66, 67 GP-16 16, 52
GP-6 39, 61, 84, 89 GP-17 31, 59
GP-7 52, 56, 70, 72 GP-18 35, 67
GP-8 11, 16, 39 GP-19 45, 72
GP-9 16, 51, 59 GP-20 51, 59
GP-10 26, 45, 66 GP-21 58, 66
GP-11 31, 72, 83 GP-22 51
GROUP 2 SAMPLES (CIN1)
Sample Code HPV genotypes detected
by Linear Array
Sample Code HPV genotypes
detected by
Linear Array
CIN1-1 33, 45, 59, 71, 83 CIN1-7 39, 81
CIN1-2 16, 51, 59, 81 CIN1-8 51, 53
CIN1-3 11, 70, 83 CIN1-9 70, 83
CIN1-4 16, 39, 66 CIN1-10 16
CIN1-5 61, 72, 84 CIN1-11 59
CIN1-6 16, 53 CIN1-12 89





Sample Code HPV genotypes
detected by
Linear Array
CC-1 16, 54, 70 CC-3 39, 71
CC-2 16, 18 CC-4 16
In bold: HPV genotypes classified as carcinogenic to humans by the IARC (group 1);
in italics: possibly carcinogenic to humans (group 2B)
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PGMY primers. As depicted in Table 3, three out of the
nine mutations were non-synonymous. Moreover, nine
HPV62-L1 contigs from the region amplified with FAP
primers revealed 10 mutations, five of them non-
synonymous (Table 3).
To study whether the HPV62 that infects the Mexican
population is a variant of the virus, the whole conserved
HPV62-L1 ORF (1690 bp amplicon) from genomic DNA
of a cervical sample was amplified and sequenced
(HPV62-L1 P9). A total of 17 nucleotide changes were
detected in HPV62-L1: four non-synonymous c.250A >G
(pT84A), c.263C >G (p.A88G), c.1139A >G (p.K380R)
and c.1489G >A (p.A497T); and 13 synonymous
c.111G >A, c.117C > T, c.126 T > C, c.324C > T, c.627C >
T, c.663G >A, c.1014 T > C, c.1017G >A, c.1161C > T,
c.1416A >G, c.1425 T > A, c.1443 T > C, c.1497A > C
(Fig. 2a). The first 3 amino acid substitutions are in the
same spatial region in L1, while the last substitution is in
the C-terminal domain, as shown by protein structure
prediction (Fig. 2b, c, d). None of the four amino acid
changes affect the tertiary structure of the L1 protein
according to the predicted models.
Nucleotide variations in HPV62-E6 and HPV62-E7
The E6 and E7 genes amplified from genomic DNA of
13 cervical samples infected with HPV62 were purified
and sequenced to detect nucleotide variations in the
HPV62 that circulates in Mexico. Altogether, seven
nucleotide changes were identified in HPV62-E6, two of
which were non-synonymous and led to an alteration in
Fig. 1 Frequency of HPV genotypes found in coinfection with HPV62.
The graphic depicts the number of samples in which each HPV
genotype was found together with HPV62
Table 2 HPV genotypes detected in samples from cervical cancer that were positive to HPV62 by NGS
Sample code HPV types found by Linear Array HPV types found by NGS Reads using FAP primers Reads using PGMY primers Total Reads
CC-1 16, 54, 62, 70 16 - 174 174
33 - 1 1
54 776 3 779
62 105 - 105
70 163 348 511
118 2 - 2
CC-2 16, 18, 62 16 9 481 490
62 895 3 898
CC-3 39, 62, 71 16 - 50 50
39 - 2 2
62 1086 218 1304
71 - 98 98
81 2 - 2
CC-5 33 12 21 - 21
21 1069 - 1069
33 1 507 508
62 3 - 3
Reads obtained from each HPV type by using FAP or PGMY11/09 primers are detailed for each sample. Linear Array results are also included
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Table 3 Genetic mutations found in the 5′ and 3′-ends of HPV62-L1
Nucleotide changes (PGMY primers) Amino acid
change
Number of samples with the





Number of samples with
the mutation n = 9
c.969 T > C 2 c.250A > G p.T84A 9
c.987A > C * p.E329D 3 c.263C > G p.A88G 7
c.1017G > A 1 c.265A > T p.T89S 1
c.1071 T > C * 3 c.413C > T p.A138V 1
c.1104G > A 1 c.436A > G p.I146V 1
c.1236 T > C 3 c.438C > T 1
c.1256A > G p.H419R 4 c.468A > G 1
c.1279A > G * p.T427A 1 c.495A > T 5
c.1287A > G 3 c.495A > G 1
c.516C > A 1
Nucleotide changes are shown in samples amplified with PGMY or FAP primers. The amino acid changes are described for those with non-synonymous mutations.
The number of samples that carry each nucleotide change are included. (*) Already reported mutations
Fig. 2 Sequence and structure alignment of HPV62 L1 protein. a Protein sequence alignment of the AY395706 NCBI sequence (HPV62-L1 REF) with
that obtained from cervical sample P9 (HPV62-L1 P9); dots indicate matching residues, amino acid changes are darkened. b Structure alignment of
both 503 amino acid complete proteins (HPV62-L1 REF in red and HPV62-L1 P9 in grey) and location of the four detected mutations shown as yellow
dots. c Magnification of the structure alignment region containing the mutated amino acids threonine (p.T84A), alanine (p.A88G), lysine (p.K380R); and
d) alanine (p. A497T)
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the protein sequence (c.157C > T, p.R53W and c.404A >
G, p.Y135C). Regarding HPV62-E7, three nucleotide
changes were detected and one of them affected the
protein sequence (c.125C > G, p.A42G) (Table 4). The
non-synonymous changes were present in all the sam-
ples, while the other nucleotide variations that do not
change the amino acid were found only in some of them.
The genetic sequences of E6 and E7 from HPV62 ampli-
fied from the 13 samples were translated into protein
and aligned to the reference sequence for an easier
visualization of the nucleotide changes and their location
(Fig. 3). Finally, to visualize the relationship between all
HPVs from Alpha-3 species and the HPV62 sequences
obtained from the 13 cervical samples, a phylogenetic
tree was built based on E6/E7 gene sequences (Fig. 4).
Discussion
A fragment of the L1 ORF ─MY09/11 region─ of
HPV62 was first sequenced in 1994 and the complete gen-
ome was isolated and sequenced to characterize the novel
HPV type 62 in 2004 [13, 24]. In 2006, the Linear Array
HPV Genotyping Test was launched; an assay that identi-
fies up to 37 HPV genotypes in cervical samples, including
HPV62. HPV62 belongs to the Alphapapillomavirus
genus, species 3 group (α-3 group) together with HPV 61,
72, 81, 83, 84, 86, 87, 89, 102 and 114.
In the present study, from 578 HPV positive samples
obtained from general population, CIN1 and CC women,
the HPV62 frequency found with LA was 7.6, 8, and
4.6%, respectively, showing that this genotype has an im-
portant prevalence in Mexico; and it is mainly found in
coinfection with HR-HPV genotypes (Table 1 and Fig. 1).
Importantly, by using NGS, 11 out of 48 individually
sequenced CIN1 samples were also positive for HPV62,
despite only 8 of them were positive for this HPV
genotype by Linear Array; moreover, concerning CC sam-
ples, only 1 of the 4 HPV62 positive samples detected by
NGS, was positive with the last methodology. Therefore,
the frequency of HPV62 could be underestimated. It is
worth mentioning that, because cervical cancer cells were
collected from cervical swabs and not from biopsies, the
samples may contain normal cells together with cancer
cells, so this could be a limitation of this study, since it is
not possible to know which cells each HPV is infecting.
When HPV62 was characterized, it was one of the ten
most prevalent HPV types detected in women with
normal Pap smears from Costa Rica and New Mexico
[13]. Later, more studies supported this finding. In the
Italian population, HPV62 was detected in 1.5% of high-
grade squamous intraepithelial lesions and also in 1.5%
of CC, being the only LR-HPV found in CC samples
[25]. There was no HPV62 detection in samples without
cervical lesions in both populations. Among LR-HPV
types detected in the Northern Indian population,
HPV62 was the most common (10.5% of HPV positive
samples) and in Egypt HPV62 was also the most preva-
lent LR-HPV among HPV positive women (17.4 and
9.7% in two different research works) [26–28]. In Thai
women, HPV62 is also among the most frequent LR-
HPV (11.3% of HPV positive samples) [29]. Another in-
teresting result was found in females from the United
States where the most common HPV type was HPV62
(found in 6.5% of all the subjects, where 42.5% are HPV
positive) [30]. In Croatian women, HPV62 was among
the most prevalent LR-HPVs in women with abnormal
cervical cytology (23.3%) [31]. In Northeast Brazil,
HPV62 prevalence among the overall population was of
3.6% and in Korea, 2% of atypical squamous cell and
low-grade squamous intraepithelial lesions were HPV62
positive [32, 33]. In Mexico, a IMSS Research Network
Table 4 Nucleotide changes found in HPV62-E6 and HPV62-E7 gene sequences from 13 cervical samples infected with HPV62 (P1-P13)
compared to the reported HPV62 genome (AY395706, NCBI)
Mutations P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13
HPV62-E6
c.27G > A ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
c.37 T > C ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
c.157C > T* ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
c.177 T > C ✓ ✓
c.199 T > C ✓ ✓ ✓ ✓ ✓
c.201G > C ✓ ✓ ✓ ✓ ✓
c.404A > G* ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
HPV62-E7
c.125C > G* ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
c.183 T > C ✓
c.199A > C ✓ ✓ ✓ ✓ ✓
(*) Nucleotide substitutions that alter protein sequence
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report on HPV, including 822 women, found HPV62
infection in 3.1% of women without cervical lesions, in
5.1% with CIN1, in 6.7% with CIN3 and in 0.8% in CC
samples [14].
All these studies agree in the high frequency of
HPV62 in cervical samples and its omnipresence in all
kind of diagnosed samples; it is therefore of great inter-
est to further study this genotype.
This work describes novel nucleotide changes in the
HPV62-L1 complete gene (1512 bp). The 17 variations
identified in the L1 ORF amplified from one sample
determine a difference of 1.12% (17/1512 bp) compared
to the reference sequence. A nucleotide sequence differ-
ence of 1% or more would define a new variant lineage,
but according to the recommended new HPV variant
classification criteria, the complete genome (and not
only the L1 ORF) has to be sequenced [10]. The align-
ment of 20 HPV62-L1 sequences obtained by NGS using
PGMY or FAP primer pairs from 16 cervical samples
revealed the presence of a total of 19 mutations, 8 of
them being non-synonymous. Interestingly, to our
knowledge, only 3 out of the 19 mutations have been
Fig. 3 Protein alignment of HPV62-E6 and HPV62-E7. a Alignment of the HPV62-E6 reference protein sequence from AY395706 genome (HPV62-E6 REF)
relative to the HPV62-E6 from 13 cervical samples (HPV62-E6 P1-P13). Amino acid changes p.R53W and p.K135C are shown. b Alignment of the HPV62-E7
reference protein sequence (HPV62-E7 REF) relative to the HPV62-E7 from the same 13 cervical samples (HPV62-E7 P1-P13). Amino acid change p.A42G is
shown. Dots indicate matching residues and dashes indicate that no information is available for the corresponding region. Arrows point to cysteines that
form the zinc binding domains
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previously described [34]. It is worth mentioning that
concerning those nucleotide changes, there was not a
different distribution between CIN1 and CC samples,
the mutations were distributed randomly among them.
Concerning HPV62-E6 and -E7 ORFs, the presence of
genetic variations is described for the first time in the
present study. Specifically, concerning HPV62-E6,
non-synonymous nucleotide changes c.157C > T
(p.R53W) and c.404A > G (p.Y135C) were found; add-
itionally, c.125C > G (p.A42G) substitution in HPV62-
E7 was found in all the 13 samples under study.
However, the c.404A > G (p.Y135C) substitution that
leads to a change of a tyrosine by a cysteine in all
the 13 analyzed samples is located in a key position
essential for the formation of a zinc binding domain
which needs two CxxC motifs. Indeed, eight cysteines
involved in the formation of two zinc binding sites in
E6 protein are conserved among the different HPV
types and the seventh cysteine in HPV62 is located in
position 135, where a tyrosine was reported instead
[12, 35]. HPV62 was originally characterized with the
overlapping PCR method and according to the
described methodological process, PCR products were
visualized with UV illumination in agarose gels before
product purification, ligation into pGEM-Teasy vector
and sequencing. UV radiation is a strong mutagen
that can induce conversion from one base to another
[36]. Therefore, the adenine reported in position 404
of the reference genome could probably be due to a
spontaneous change caused by UV radiation. The
reference AY395706 HPV62 genomic sequence could
have been reported with some mistakes and the three
non-synonymous changes in E6 and E7 described in
this work might be found of the HPV62 sequence
worldwide. Earlier this year, a new complete HPV62
genome sequence has been uploaded in the GenBank
database (KU298924.1) [15]; in which some of the
nucleotide changes described in the present research
are confirmed.
These findings open a new door to the study of LR-
HPVs commonly found in HPV positive women. To
date, oncogenic HPVs have been studied primarily,
thus information on rare or LR-HPVs is limited,
although they are often more prevalent than HR-
HPVs. When found in coinfection with other HPV
types, these non-oncogenic viruses may play an
important role in the progression or regression of a
cervical lesion, but this remains unstudied. Undoubt-
edly, more research is needed in this field, particularly
with respect to the E5, E6 and E7 proteins and their
different domains shared between HR-HPVs and LR-
HPVs to understand their way of action. Furthermore,
the L1 major capsid protein and its different variants
may influence crucial steps of the viral infection cycle
due to altered affinity to other proteins.
HPV infection in a single patient often comes along
with more than one HPV genotype. Hence, clustering of
the different genotypes present in a single sample might
be crucial for understanding the roles of each genotype
in carcinogenesis. This will lead to a better understand-
ing of possible interactions between HPVs found in coin-
fections, both low and high risk.
Conclusions
HPV62 was found in Mexican women who attended
their preventive routine check-up and in women with
Fig. 4 Phylogenetic tree showing reference HPVs from alpha-3 species and 13 HPV62 Mexican sequences based on E6/E7 genes. The evolutionary
history was inferred by using the Maximum Likelihood method based on the Tamura-Nei model [37]. The tree is drawn to scale, with branch lengths
measured in the number of substitutions per site. The analysis involved 18 nucleotide sequences. Evolutionary analyses were conducted in MEGA7 [38].
The GenBank accession number of each HPV genotype reference from alpha-3 species is included in parentheses
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cervical cancer. In the general population and in the
CIN1 samples, HPV62 was often present both in single
and multiple infection; however, in cervical cancer sam-
ples it was only found in coinfections with at least one
HR-HPV type. To our knowledge, this is the first study
that describes the presence of mutations in HPV62-E6
and -E7 genes. Moreover, newly observed nucleotide
changes in the L1 gene were found to alter the L1
protein sequence. Upcoming discoveries in this field will
complement the current information on variants of
human papillomavirus and on still unclassified genotypes
in their carcinogenicity risk to humans.
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